Developing educational and research initiatives that unite oncologists and accelerate breakthroughs in MBC
Nationwide
Joined June 2013
- Tweets6.8K
- Following1.6K
- Followers2K
- Likes5.2K
Pinned Tweet
We are excited to announce the release of MBC DART (Discovery & Accelerating Research Together): Insight to Impact — A Strategic Action Plan for metastatic #breastcancer @mbcalliance @washumedicine
einpresswire.com/article/928…
theresa's research retweeted
Breast cancer completely cut out of the NIH funding for vaccines. The largest killer of women. We deserve better. @NIH @SecKennedy @FLOTUS @KomenAdvocacy where is the outrage??
beckershospitalreview.com/qu…
Thank you @GovMikeKehoe for recognizing #metastatic #breastcancer awareness day! Had a great day with @SitemanCenter @KoontzCenter and especially the patients who joined us as well.
theresa's research retweeted
Living with metastatic breast cancer takes more than clinical care — it takes community. Siteman Cancer Center’s MBC Empowerment Initiative connects patients with resources, support groups and a team that understands. @WashUMedicine siteman.washu.edu/how-sitema…
We are excited to announce we have a two day event planned for MBC AWARENESS DAY #BreastCancerAwarenessMonth . Day 1 in Houston and day two in St. Louis . Both will also be available online as well . Click the link for more details and get registered.
theresasresearch.org/mbc-day…
theresa's research retweeted
Thrilled to see this in print. Honored to partner with @elmayermd @stolaney1 and our fabulous colleagues and partners at Roche/Genentech on this practice changing trial. Combo vs combo proves a more effective ET for mESR1 dse. @OncoAlert @OncBrothers
In ER-positive, HER2-negative advanced breast cancer, giredestrant, an ER degrader and full ER antagonist, plus everolimus led to longer progression-free survival than standard endocrine therapy–everolimus; safety was similar. Full phase 3 evERA Breast Cancer trial results: nej.md/47ryfbF
ALT A graph from an Original Article published in the New England Journal of Medicine article titled "Giredestrant plus Everolimus in Advanced Breast Cancer." The graph shows progression-free survival among patients with ESR1-mutated tumors. The trial name, evERA Breast Cancer, is in parentheses after the title. The NEJM identity sits at the bottom.
theresa's research retweeted
In a recent guest post, Individual Advocate Member Marybeth Gilliam reflects on why having patient advocates “in the room” matters—and how access to scientific meetings can help patients feel more informed, empowered, and hopeful.
Read her post: mbcalliance.org/guestblogpos…
theresa's research retweeted
Katie E. is sharing her experiencing living with MBC and the invisible side effects that take their toll. Explore her story, and those of others living with MBC, through our international storytelling project, #ThisIsMyMBC.
Explore more: MBCAlliance.org/MyMBC
theresa's research retweeted
Now available! 📚 The Insider’s Guide to Metastatic Breast Cancer provides information about approved therapies, scientific studies, cutting edge research, clinical trials, and palliative care.
Learn more about the author & get a free PDF: mbcalliance.org/projects/the…
theresa's research retweeted
We celebrate the life and work of advocate member Elissa Chandler, who passed away on August 31. Her passion for research and compassion for others touched many, helping to advance work on triple-negative breast cancer and brain metastases.
Read more: MBCAlliance.org/news/in-memo…
theresa's research retweeted
We celebrate the life and work of advocate member Jill Tirabassi, who passed away on September 7, 2026. A dedicated physician, researcher, educator and advocate, Jill’s work helped raise awareness for postpartum breast cancer.
Read more: MBCAlliance.org/news/in-memo…
theresa's research retweeted
Join Dr. Ann Partridge (@AnnPartridgeMD), and Miranda McKeon for a free @BCRFcure webinar, “Younger Women and Breast Cancer: A Race for Answers.”
📅 Thursday, September 24 | 12 p.m. ET
Together, they’ll separate fact from fiction, discuss risk and prevention, and explore what advances in treatment mean for longevity and quality of life. The conversation will also cover menopause, hormone replacement therapy, and other topics younger women are asking about today.
Learn more and register: us06web.zoom.us/webinar/regi…
#BreastCancer #BreastCancerInYoungWomen
theresa's research retweeted
Last year we lost our friend Shirley Mertz, who would have been 80 on 16/9. US President Barack Obama named her a “Champion of Change in Breast Cancer” for her work in ABC, and she received our ABC6 Award. Shirley's legacy of work for people with ABC lives on-we are so grateful.
theresa's research retweeted
FDA grants accelerated approval to Etcamah (camizestrant) + CDK4/6i (abemaciclib, palbociclib, ribociclib) for HR+/HER2- advanced BC upon ESR1 mutation detected during AI + CDK4/6i therapy, by FDA-authorized test.
Pro: mPFS 16 vs 9.2 mo per label. In SERENA-6, final PFS2 25.7 vs 19.1 mo (HR 0.63) and 46% lower risk of deterioration in global health status/QOL.
Con: Accelerated approval, OS immature, confirmatory trials required. Boxed warning for irregular heart rhythm with certain concomitant meds, plus bradycardia.
First trial to intervene on molecular resistance in breast cancer before clinical PD.
#bcsm
After #ASCO25 Plenary, Camizestrant is now @US_FDA ✅ based off #SERENA6: PhIII, Camizestrant + CDK4/6i vs AI + CDK4/6i for emerging ESR1m before progression.
- mPFS2: 25.7mos vs. 19.1mos (HR: 0.63)
- mPFS: 16.8mos vs. 9.2mos (HR: 0.45)
#OncTwitter #bcsm #MedX @OncoAlert
theresa's research retweeted
Intramural NCI, Center for Cancer Research (CCR) is looking to hire tenure track investigators, with Ph.D or MD or MD/Ph.D. Through the NIH Stadtman Scholars Program. Please see below for details. ccr.cancer.gov/careers/resea…
theresa's research retweeted
A treasured 🎁 arrived yesterday: Anne Loeser’s(@AnnePCDI) “The Insider’s Guide to Metastatic Breast Cancer.”
Anne died from MBC in 2023. I had the privilege of working w/ @amybeumer, who died from MBC in June 2026, & @stage4kelly to update Anne’s book.
💔 that neither got to see it published. Grateful to have called them both friends. Their legacies live on. #bcsm @The_Right_Dose
theresa's research retweeted
🙌Hey @utswcancer @UTSWMedCenter @UTSWCancerBio @UTSWHemeOnc @UTSWScience @UTSW_Pathology @UTSWMolBiol @utswimmuno
don't miss TOMORROW'S #KomenBreastCancerForum feat. @BalkoLab @VUMChealth. #AntibodyDrugConjugates #CancerImmunology #BreastCancer #CancerImmunotherapy
theresa's research retweeted
With 6 FDA approvals in breast cancer already in 2026, it was time to update the breast cancer treatment algorithms. It's a great problem to have when innovation is moving so fast that it's hard to keep up #bcsm @OncoAlert @DFCI_BreastOnc
theresa's research retweeted
We submitted comments to @FDA's draft guidance on leveraging prior knowledge in cell and gene therapy development. The concepts build on a risk-based framework from our 2023 cell therapy meeting, where panelists described challenges sponsors experience: bit.ly/4ikxoAf.
theresa's research retweeted
ctDNA dynamics during neoadjuvant therapy may help predict response and identify patients at higher risk of relapse, supporting future ctDNA-guided treatment strategies @JCOOA_ASCO @MridulaGeorgeMD
ascopubs.org/doi/pdf/10.1200…
theresa's research retweeted
ELECTRA Shows CNS Activity With Elacestrant and Abemaciclib in Brain Metastases - Sarah Sammons
@drsarahsam
oncodaily.com/science/sarah-…
